Evidence map›Paper›PMID 41560795›Full record

ReviewMaterials today. Bio2026

NIR imaging-guided carbon monoxide nanomedicine: Design strategies, stimuli-responsive release, and multimodal synergistic therapies for precision disease treatment.

Yaoqiang Li, Yeneng Dai, Bo Wang, Nan Zhang, Kangyi Yan, Haoqin Chen, Hongrong Shi, Hongli Chen, Qingzhi Wang, Jierui Yan and 6 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Yaoqiang LiXinxiang Key Laboratory of Biomedical Materials, Nanobiomedical Materials Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, China.
Yeneng DaiMoE Frontiers Science Center for Precision Oncology, Cancer Centre, Faculty of Health Sciences, University of Macau, Macau, Taipa, 999078, China.
Bo WangDepartment of Chemistry, Korea University, Seoul 02841, South Korea.
Nan ZhangXinxiang Key Laboratory of Biomedical Materials, Nanobiomedical Materials Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, China.
Kangyi YanXinxiang Key Laboratory of Biomedical Materials, Nanobiomedical Materials Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, China.
Haoqin ChenXinxiang Key Laboratory of Biomedical Materials, Nanobiomedical Materials Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, China.
Hongrong ShiXinxiang Key Laboratory of Biomedical Materials, Nanobiomedical Materials Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, China.
Hongli ChenXinxiang Key Laboratory of Biomedical Materials, Nanobiomedical Materials Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, China.
Qingzhi WangXinxiang Key Laboratory of Biomedical Materials, Nanobiomedical Materials Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, China.
Jierui YanTCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
Xiaobo WangInnovative Institute of Chinese Medicine and Pharmacy/Academy for Interdiscipline, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
Peiyang GaoDepartment of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
Gongcheng MaXinxiang Key Laboratory of Biomedical Materials, Nanobiomedical Materials Research Center, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, China.
Ya HouTCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
Qihang DingDepartment of Chemistry, Korea University, Seoul 02841, South Korea.
Qi ZhaoMoE Frontiers Science Center for Precision Oncology, Cancer Centre, Faculty of Health Sciences, University of Macau, Macau, Taipa, 999078, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endogenous gaseous molecules, especially carbon monoxide (CO), exhibit unique therapeutic potential in regulating cancer, infections, and inflammation owing to their dose-dependent bioactivity and multi-faceted mechanisms. However, challenges in spatiotemporal control and real-time monitoring of CO delivery hinder clinical translation. The integration of near-infrared II (NIR-II) imaging with CO nanodelivery systems provides a promising avenue for precise visualization and controlled gas therapy, offering deep tissue penetration, high resolution, and a favorable signal-to-noise ratio for guided therapy. This review systematically summarizes recent advances in NIR-II-guided CO nanoplatforms, focusing on design strategies, including polymers, core-shell structures, Metal-Organic Frameworks (MOFs), and peptide-modified systems, as well as their stimulus-responsive mechanisms across exogenous light, microenvironmental, and organelle-targeted delivery. Furthermore, we highlight synergistic therapeutic strategies combining CO gas therapy with photothermal, photodynamic, chemodynamic, and immunotherapy under NIR-II guidance, demonstrating enhanced therapeutic efficacy while minimizing systemic toxicity. Despite these advances, significant challenges remain, including the lack of subcellular-level CO monitoring, incomplete synergy between NIR-II imaging and CO bioactivity, and hurdles in clinical translation. This review aims to provide critical insights into the rational design of NIR-II-guided CO nanodelivery systems, offering a blueprint for their future development towards precise, safe, and effective disease treatment.

Indexed as

Carbon monoxideGas therapyNanoparticlesNIR-IIPhototherapy

Identifiers

PMID41560795
PMCPMC12813320

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.